(Q39781613)

14 September 2017

title

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha (English)

1 reference

14 September 2017

Enrica Balza

1

1 reference

14 September 2017

Barbara Carnemolla

2

1 reference

14 September 2017

Lorenzo Mortara

3

1 reference

14 September 2017

Patrizia Castellani

4

1 reference

14 September 2017

Debora Soncini

5

1 reference

14 September 2017

Roberto S Accolla

6

1 reference

14 September 2017

Laura Borsi

7

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

International Journal of Cancer

14 September 2017

published in

1 reference

14 September 2017

volume

127

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

101-110

1 reference

Induction chemotherapy in metastatic neuroblastoma--does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC).

14 September 2017

cites work

1 reference

Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal

21 January 2018

1 reference

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.

21 January 2018

1 reference

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

21 January 2018

1 reference

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

21 January 2018

1 reference

Structure of tumour necrosis factor

21 January 2018

1 reference

Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts

21 January 2018

1 reference

Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1

21 January 2018

1 reference

TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens

21 January 2018

1 reference

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

21 January 2018

1 reference

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.

21 January 2018

1 reference

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

21 January 2018

1 reference

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

21 January 2018

1 reference

Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen

21 January 2018

1 reference

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

21 January 2018

1 reference

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome

21 January 2018

1 reference

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.25018

1 reference

14 September 2017

1 reference